Navigation Links
Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimer's
Date:6/3/2009

Tampa, Florida (June 2, 2009) --Researchers affiliated with Natura Therapeutics, Inc., Tampa, Florida, and the University of South Florida (USF) have jointly received a one-year, $110,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health's (NIH) National Center for Complementary and Alternative Medicine to continue studying TeaMem, a compound made from green tea.

TeaMem holds promise for preventing and treating Alzheimer's disease (AD), a disease that the Alzheimer's Association says today affects as many as 5.2 million Americans. The most recent grant follows two other NIH grants to develop and evaluate TeaMem -- a $160,000 grant for 2007-2008 and a $140,000 grant for 2008-2009. The research conducted under these three grants was also supported through matching funds from the Florida High Tech Corridor Matching Grants Research Program.

According to Jun Tan, M.D., Ph.D., a professor in the USF Department of Psychiatry and Behavioral Medicine, and one of the grant's principal investigators, the grant will be used to investigate the role of TeaMem in opposition to cleavage of the amyloid precursor protein protelysis (APP) into Abeta peptides and resultant cerebral amyloidosis, a process identified as a key feature in AD pathology.

"Our recent findings suggest that strategies that promote non-amyloidogenic/alpha-secretase APP processing may have significant potential for the treatment of AD," said Tan.

This SBIR grant, the most recent of three NIH grants, allows the continuing development of TeaMem and its evaluation in the test tube (in vitro). The latest grant provides for testing in vitro and in the body (in vivo) using mouse models to evaluate the effects of TeaMem.

Early tests will evaluate TeaMem in promoting non-amyloidogenic APP alpha-secretase proteolysis and then examine its therapeutic and preventive effects on AD pathology and cognitive impairment.

"We expect to clearly define this non-amyloidogenic mechanism and identify the potential molecular drug targets essential for formulating novel, effective treatments against AD," explained Cyndy D. Sanberg, Ph.D., senior vice president of Natura Therapeutics, Inc. and the other PI on the grant.

Tests, including cognitive tests, will use mouse models for oral administration of TeaMem to a prophylactic treatment group that will be compared to a second group with AD-like pathology. Groups will be compared for the effect of reducing AD-like pathology and behavioral impairment. The studies, said Tan, could lay the groundwork for AD clinical trials in humans in the near future.

In their 2008 report, the Alzheimer's Association (www.alz.org) noted that AD was the nation's sixth leading cause of death and predicts 10 million baby boomers will develop AD. The direct and indirect costs of AD exceed $148 billion annually, said the Association.


'/>"/>

Contact: Dr. Jun Tan
jtan@health.usf.edu
813-974-9326
University of South Florida Health
Source:Eurekalert

Related medicine news :

1. The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally
2. The First High Performance Sports Water - AquaHydrate - to Offer Ionic Minerals Through Exclusive Agreement With Natural Foods Pioneer, Trace Minerals Research
3. New Journal of Natural Medicine Launched This June, Promotes Natural Therapy
4. Chocolate Milks Natural Muscle Recovery Benefits Match or May Even Surpass a Specially Designed Carbohydrate Sports Drink
5. Buster Brands Launches Natural Alternatives to Acetaminophen Pain Killers
6. US Farms, Inc. Announces Membership to Natural Products Association
7. Sun Shower(TM) All Natural Super Blends Now Light N Healthy
8. Introducing COPPERTONE(R) NutraShield(R) With Dual Defense(R), New Sunscreen Line With Antioxidants To Help Promote Natural Skin Repair
9. Natural Alternatives International, Inc. Announces Fiscal 2009 Q3 Results
10. Super Lice Repelled by All-Natural Products First Ever Independent Study Shows
11. When Stomach Flu Strikes, Work With, Not Against, Body's Natural Defenses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: